Author

B. Wali

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Moreno· 2 shared M. E. Davis-Gardner· 2 shared M. Ellis· 2 shared M. S. Suthar· 2 shared S. Godbole· 2 shared A. Dodson· 1 shared A. K. Nooka· 1 shared A. Mychalowych· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Moreno

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

A. Moreno, K. Manning, M. I. Azeem, A. K. Nooka, M. Ellis, R. J. Manalo, J. M. Switchenko, B. Wali, J. L. Kaufman, C. C. Hofmeister, N. S. Joseph, S. Lonial, K. M. Dhodapkar, M. V. Dhodapkar, M. S. Suthar

This study examines how SARS-CoV-2 booster vaccines affect antibody profiles in myeloma patients, finding improved binding but not neutralization against variants.

bioRxiv · Aug 17, 2023 · PreprintImmunology

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

M. E. Davis-Gardner, L. Lai, B. Wali, H. Samaha, D. Solis, M. Lee, A. Porter-Morrison, I. T. Hentenaar, F. Yamamoto, S. Godbole, D. C. Douek, F. E.-H. Lee, N. Rouphael, A. Moreno, B. A. Pinsky, M. S. Suthar

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

bioRxiv · Oct 31, 2022 · PreprintImmunology